Loading...
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial.
Collett, L Howard, D Munir, T McParland, L Oughton, J Rawstron, A Hockaday, A Dimbleby, C Phillips, D McMahon, K
Collett, L
Howard, D
Munir, T
McParland, L
Oughton, J
Rawstron, A
Hockaday, A
Dimbleby, C
Phillips, D
McMahon, K
Citations
Altmetric:
Abstract
Treatment of chronic lymphocytic leukaemia (CLL) has seen a substantial improvement over the last few years. Combination immunochemotherapy, such as fludarabine, cyclophosphamide and rituximab (FCR), is now standard first-line therapy. However, the majority of patients relapse and require further therapy, and so new, effective, targeted therapies that improve remission rates, reduce relapses, and have fewer side effects, are required. The FLAIR trial will assess whether ibrutinib plus rituximab (IR) is superior to FCR in terms of progression-free survival (PFS).
Description
Date
2017-08-22
Publisher
Collections
Files
Keywords
Type
Article
Citation
Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. 2017, 18 (1):387 Trials